LONDON--AstraZeneca PLC (AZN.LN) shares rose 5.5% on Friday after the company said the U.S. food and drug administration has accepted the first license application for its antibody called durvalumab, meant for the treatment of patients with bladder cancer.

Shares at 1515 GMT up 225.50 pence, or 5.6%, at 4346 pence valuing the company at GBP54.9 billion.

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

December 09, 2016 10:31 ET (15:31 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Astrazeneca Charts.